Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211
Open Access
- 15 July 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 196 (2) , 304-312
- https://doi.org/10.1086/518797
Abstract
Background. Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study.Methods. The present stKeywords
This publication has 0 references indexed in Scilit: